Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate

Drug Profile

Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate

Alternative Names: AIC; Amb a 1 Immunostimulatory Conjugate; TOLAMBA

Latest Information Update: 20 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Class Allergens; Antiallergics; DNA vaccines; Immunoconjugates; Oligonucleotides; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seasonal allergic rhinitis

Most Recent Events

  • 20 May 2008 Discontinued - Phase-II for Seasonal allergic rhinitis in Canada (SC)
  • 24 Oct 2007 Phase-II clinical trials for Seasonal allergic rhinitis in Canada (SC)
  • 08 Mar 2007 No development reported - Phase-II/III for Seasonal allergic rhinitis in Canada (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top